(Q39142018)

9 September 2017

title

Histiocytoses: emerging neoplasia behind inflammation (English)

1 reference

9 September 2017

0 references

10

Zahir Amoura

1 reference

9 September 2017

1

Julien Haroche

1 reference

9 September 2017

Fleur Cohen-Aubart

2

1 reference

9 September 2017

Barret J Rollins

3

1 reference

9 September 2017

Jean Donadieu

4

1 reference

9 September 2017

Frédéric Charlotte

5

1 reference

9 September 2017

Ahmed Idbaih

6

1 reference

9 September 2017

Augusto Vaglio

7

1 reference

9 September 2017

Omar Abdel-Wahab

8

1 reference

9 September 2017

Jean-François Emile

9

1 reference

9 September 2017

publication date

1 February 2017

1 reference

Lancet Oncology Commission

9 September 2017

published in

1 reference

9 September 2017

volume

18

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

e113-e125

1 reference

Recurrent BRAF mutations in Langerhans cell histiocytosis

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Spontaneous remission of multi-system histiocytosis X

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Spontaneous regression of langerhans cell histiocytosis in a neonate with multiple bony lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Genomic Alterations in Langerhans Cell Histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Somatic activating ARAF mutations in Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Clonal status and clinicopathological feature of Erdheim-Chester disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

The development and maintenance of resident macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cell(s) of Origin of Langerhans Cell Histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Incidence of Langerhans cell histiocytosis in children: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

A New clinical score for disease activity in Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

MRI features of neurodegenerative Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Risk factors for diabetes insipidus in langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cognitive outcome of long-term survivors of multisystem langerhans cell histiocytosis: a single-institution, cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

How I treat Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Central nervous system disease in Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Neuropathology of CNS disease in Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Medical management of langerhans cell histiocytosis from diagnosis to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

A randomized trial of treatment for multisystem Langerhans' cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Erdheim–Chester Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Treatment of Erdheim-Chester disease with long-term high-dose interferon-α

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Scintigraphic diagnosis of Erdheim-Chester disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Imaging of thoracoabdominal involvement in Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

[Erdheim-Chester disease].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

IgG4-related disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Retroperitoneal fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Treatment of Erdheim-Chester disease with cladribine: a rational approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Tumor Necrosis Factor α As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Updates on histiocytic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

A case of H syndrome showing immunophenotye similarities to Rosai-Dorfman disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Sinus histiocytosis with massive lymphadenopathy: complete response to low-dose interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Rosai-Dorfman disease successfully treated with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930031-1

7 January 2021

10.1016/S1470-2045(17)30031-1

Identifiers

DOI

1 reference

9 September 2017

1 reference